SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 86.38+2.9%Nov 10 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmhollen who started this subject12/19/2001 1:41:00 AM
From: jmhollen   of 347
 
Mooooo... GMED / Cashcowmag.com news - Dec 14th 01

Cashcow Magazine Online
301-1465 Ellis Street
Kelowna, BC V1Y-2A3
News Release - FOR IMMEDIATE RELEASE

Stuart Gray, President of Cashcowmag.com stated, "We are very excited that we are able to profile GenoMed Inc. Their listing is a very unique addition to our STOCKS TO WATCH section of our Website. We have been looking for a Company that is on the leading edge in biotechnology. In addition GenoMed Inc. has more clinical experience than the vast majority of other biotech companies. GenoMed Inc. already owns 3 potential blockbuster clinical provisional patents that are ready for immediate licensing. Any one of these patents could cause some major media publicity."


GenoMed Inc. is a biotechnology Company that has one foot in science and the other foot in clinical medicine. As a result, we have already seen how knowledge of a disease gene can pay off in improved patient outcomes. Dr. Moskowitz, a nephrologist of GMED, treated his own 1,000 patients with his disease gene knowledge, with dramatic results. For example, the rate of progression of Kidney disease due to high blood pressure was reduced by an average of 400% in both African and Caucasian men. Through this new treatment, patients expected to reach dialysis in 4 years, were delayed an average of 16 years to reach end-stage kidney-disease!

Targeted Diseases: Collections are underway for the following Diseases.
Type 2 Diabetes
End-stage Kidney Disease due to type 2 Diabetes.
Heart Attack due to Type 2 Diabetes.
Stroke due to Type 2 Diabetes.
High Blood Pressure.
End-stage Kidney Disease due to high blood pressure.
Heart Attack due to high blood pressure.
Breast Cancer.
Lung Cancer.
Prostate Cancer.
Colon Cancer.


GenoMed Inc – GMED: PINK SHEETS currently trades at .09 cents per share. The Company has engaged the prestigious law firm of Hamilton, Lehrer, & Dargan, P.A. to complete the filings necessary to become a listed company with the NASDAQ OTC Bulletin Board.

Cashcowmag.com is an innovative online financial magazine dedicated in featuring new and emerging growth stocks to the investing public. Every company featured has a unique product or service. Cashcowmag.com offers many FREE financial related services such as Web based Email, an investment club, financial chat forum, stock quotes, message board, daily news, audio interviews and more.

For more information on GenoMed Inc's Corporate Profile click below.

cashcowmag.com er_gmed.html

Or get a quote pinksheets.com

:: DISCLAIMER ::
Cashcowmag.com's Website is for informational purposes only and for investment advice be sure to consult with your Broker or Financial adviser
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext